Get the Stockscreener App
1.45
4.32%
0.06
After Hours:
1.45
Calidi Biotherapeutics Inc stock is traded at $1.45, with a volume of 242.87K.
It is up +4.32% in the last 24 hours and down -6.45% over the past month.
Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.
See More
Previous Close:
$1.39
Open:
$1.39
24h Volume:
242.87K
Relative Volume:
0.88
Market Cap:
$7.44M
Revenue:
-
Net Income/Loss:
$-23.36M
P/E Ratio:
-1.968
EPS:
-0.7368
Net Cash Flow:
-
1W Performance:
-3.33%
1M Performance:
-6.45%
6M Performance:
-73.67%
1Y Performance:
-92.76%
1-Day Range:
$1.35
$1.5599
1-Week Range:
$1.10
$1.69
52-Week Range:
$1.10
$46.68
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Name
Calidi Biotherapeutics Inc
Sector
Industry
Phone
(858) 794-9600
Address
4475 Executive Drive, Suite 200, San Diego
Compare CLDI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
1.45 | 7.44M | 0 | -23.36M | 0 | -0.7368 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.22 | 106.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
674.55 | 68.81B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.95 | 58.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
889.64 | 53.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.69 | 40.93B | 447.02M | -1.18B | -906.14M | -6.1812 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-23 | Initiated | H.C. Wainwright | Buy |
| Oct-09-23 | Initiated | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Stock (CLDI) Latest News
How analysts revise price targets for Calidi Biotherapeutics Inc. stockWeekly Stock Analysis & Real-Time Buy Zone Alerts - newser.com
What recovery options are there for Calidi Biotherapeutics Inc.CEO Change & Consistent Profit Trade Alerts - newser.com
Will Calidi Biotherapeutics Inc. stock outperform small cap peersJuly 2025 Analyst Calls & Free Daily Entry Point Trade Alerts - newser.com
Will Calidi Biotherapeutics Inc. stock sustain bullish trend into 2025Weekly Profit Summary & Weekly Top Performers Watchlists - newser.com
How Calidi Biotherapeutics Inc. stock reacts to stronger dollarInsider Selling & High Yield Stock Recommendations - newser.com
Calidi Biotherapeutics Unveils New Data on CLD-401 - TipRanks
Calidi Biotherapeutics, Inc. Presents New Data on CLD-401 - TradingView
Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC - The Manila Times
Calidi (NYSE American: CLDI) shares CLD-401 systemic data at SITC; IND filing anticipated by end of 2026 - Stock Titan
Analyzing recovery setups for Calidi Biotherapeutics Inc. investorsJuly 2025 Selloffs & Precise Swing Trade Alerts - newser.com
Signal strength of Calidi Biotherapeutics Inc. stock in tech scannersTrade Entry Report & Free Daily Entry Point Trade Alerts - newser.com
Will Calidi Biotherapeutics Inc. stock split increase liquidityWeekly Loss Report & Weekly Sector Rotation Insights - newser.com
Will Calidi Biotherapeutics Inc. benefit from macro trends2025 Major Catalysts & Accurate Technical Buy Alerts - newser.com
Calidi Biotherapeutics Inc. stock trendline breakdownGap Up & High Accuracy Investment Entry Signals - newser.com
Using RSI to spot recovery in Calidi Biotherapeutics Inc.Quarterly Portfolio Review & AI Driven Price Predictions - newser.com
What earnings margins imply for Calidi Biotherapeutics Inc. stock2025 Market Sentiment & Weekly High Return Opportunities - newser.com
Using data models to predict Calidi Biotherapeutics Inc. stock movementWatch List & Fast Gaining Stock Strategy Reports - newser.com
Calidi Biotherapeutics Inc.’s volatility index tracking explainedMarket Rally & Reliable Breakout Forecasts - newser.com
Multi asset correlation models including Calidi Biotherapeutics Inc.July 2025 Fed Impact & Weekly Setup with ROI Potential - newser.com
Can Calidi Biotherapeutics Inc. stock rebound after recent weaknessRecession Risk & Real-Time Market Trend Scan - newser.com
Full technical analysis of Calidi Biotherapeutics Inc. stockGap Up & Risk Controlled Stock Alerts - newser.com
Is Calidi Biotherapeutics Inc. stock supported by strong cash flowsTrade Performance Summary & Risk Controlled Swing Alerts - newser.com
What momentum shifts mean for Calidi Biotherapeutics Inc.Options Play & Free Growth Oriented Trading Recommendations - newser.com
Will Calidi Biotherapeutics Inc. stock see insider buyingTrade Exit Summary & Technical Pattern Based Buy Signals - newser.com
Calidi Biotherapeutics Inc Stock (CLDI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Cap:
|
Volume (24h):